The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells
1 Pharmacyclics, Inc., Research Department, Sunnyvale CA, 94085-4521, USA
2 Stanford University School of Medicine, Division of Immunology and Rheumatology, Stanford, CA. 94305
3 VA Palo Alto Health Care System, 3801 Miranda Avenue, Palo Alto, CA, 94304, USA
Arthritis Research & Therapy 2011, 13:R115 doi:10.1186/ar3400Published: 13 July 2011
Additional file 1:
Table S1. Immunophenotyping of splenocyte subpopulations following 18 days of treatment with PCI-32765.
Format: DOC Size: 40KB Download file
This file can be viewed with: Microsoft Word Viewer
Additional file 2:
Figure S1. Serum cytokines/chemokines from collagen-induced arthritis (CIA) mice treated with PCI-32765 at 12.5 mg/kg (n = 12) for 18 days. * P < 0.05 compared with vehicle, analysis of variance.
Format: PDF Size: 131KB Download file
This file can be viewed with: Adobe Acrobat Reader
Additional file 3:
Supplementary materials and methods. Immunophenotyping of mouse spleens from collagen-induced arthritis (CIA) models.
Format: DOCX Size: 12KB Download file
Additional file 4:
Figure S2. PCI-32765 potentially inhibits multiple pathways in the pathogenesis of rheumatoid arthritis. PCI-32765 inhibits B cell activation, and suppresses cytokine/chemokine production from monocytes, macrophages, and mast cells following immune-complex activation (modified from ). Art by Jacqueline Schaffer, M.A.M.S., medical illustrator, for Pharmacyclics Inc.
Format: TIFF Size: 7.5MB Download file